Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy

Other authors

Institut Català de la Salut

[Diaz M] Nephrology Department, Hospital Universitari Fundació Puigvert. Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Agraz I, Soler MJ] Servei de Nefrologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain.

Vall d'Hebron Barcelona Hospital Campus

Publication date

2019-03-22T12:53:47Z

2019-03-22T12:53:47Z

2019-02-01



Abstract

Anti-phospholipase A2 receptor antibody; Membranous nephropathy; Spontaneous remission


Anticòs del receptor anti-fosfolipasa A2; Nefropatia membranosa; Remissió espontània


Anticuerpo del receptor anti-fosfolipasa A2; Nefropatía membranosa; Remisión espontánea


Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in native kidney biopsies from adults. In 2009, antibodies to the M-type receptor of phospholipase A2 (anti-PLA2R) were identified in idiopathic MN patients, both within the kidney and in the circulation. The clinical course of idiopathic MN is variable and ranges from spontaneous remission to end-stage renal disease. Clinical variables such as proteinuria levels, patient sex, age and renal function at diagnosis have been associated with renal MN progression. In this editorial, we update the importance of anti-PLA2R levels as a prognostic marker in idiopathic MN at the diagnosis of the disease

Document Type

Article


Published version

Language

English

Publisher

Oxford University Press

Related items

Clinical Kidney Journal;12(1)

https://academic.oup.com/ckj/article/12/1/33/5114409

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)